Related Experiment Video

Updated: Mar 6, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Ruxolitinib and heart failure outcomes among patients with myelofibrosis

Orly Leiva1, Steven Soo2,3, Olivia C Liu2

  • 1Gill Heart & Vascular Institute, University of Kentucky College of Medicine, Lexington, KY, USA.

Leukemia & Lymphoma
|March 5, 2026
PubMed

Insights

Ruxolitinib may lower heart failure risk in myelofibrosis (MF) patients. This myeloproliferative neoplasm (MPN) treatment showed a reduced risk of heart failure hospitalization or new pulmonary hypertension.

Area of Science:

  • Hematology
  • Cardiology
  • Pharmacology

Background:

  • Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) linked to increased heart failure (HF) and pulmonary hypertension (PH) risks.
  • These cardiovascular complications contribute significantly to morbidity and mortality in MF patients.

Purpose of the Study:

  • To investigate the impact of ruxolitinib treatment on the risk of HF hospitalization or new PH in MF patients.
  • To assess the effect of ruxolitinib on all-cause mortality in this cohort.

Main Methods:

  • Retrospective cohort study of 144 MF patients without prior HF.
  • Outcomes analyzed included HF hospitalization, new PH, and all-cause death.
  • Statistical analysis used adjusted subhazard ratios and hazard ratios.

Main Results:

  • Ruxolitinib treatment was associated with a significantly lower risk of HF hospitalization or new PH (aSHR 0.27).
  • No significant association was found between ruxolitinib and all-cause death (aHR 0.85).

Conclusions:

  • Ruxolitinib treatment may reduce cardiovascular complications in MF patients.
  • Further prospective, randomized studies are necessary to confirm these findings and establish ruxolitinib's role in improving cardiovascular outcomes in MF.
Keywords:
Neoplasiamyeloid leukemias and dysplasiasmyeloproliferative disorderspharmacotherapeutics

More Related Videos

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
439
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
734
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K